BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a prominent global oncology firm, has unveiled its 2023 Responsible Business & Sustainability Report, spotlighting the company’s strategic direction, progress towards existing objectives, and its vision for achieving ambitious new targets.
This report arrives amidst a period of remarkable expansion for BeiGene. In 2023, the company reached a significant milestone, with over 1 million patients globally treated using its BTK inhibitor, BRUKINSA® (zanubrutinib), and anti-PD-1 antibody, TEVIMBRA® (tislelizumab). BeiGene is actively bolstering its global footprint, with plans to inaugurate a flagship research and development and manufacturing facility at the Princeton West Innovation Campus in Hopewell, New Jersey, in July, enhancing its presence in the United States.
John V. Oyler, Co-Founder, Chairman, and CEO at BeiGene, emphasized the company’s commitment to equitable access to impactful medicines, regardless of geographical or socioeconomic factors. He underscored BeiGene’s strategic focus on accelerating the delivery of medicines to a broader demographic in a more efficient and cost-effective manner.
BeiGene’s Responsible Business & Sustainability strategy revolves around four core pillars: Advancing Global Health, Empowering Our Colleagues, Innovating Sustainably, and Operating Responsibly. Since 2021, the company has set annual goals for each pillar and has been transparently reporting progress.
Key highlights from the 2023 report include:
- Increase in the percentage of women in Vice President and higher positions from 33% to 38% year over year.
- Establishment of a global health equity strategy.
- Surpassing 20,000 hours of employee volunteerism worldwide.
- Integration of climate risk into the Enterprise Risk Management process.
- Launch of a supplier engagement program, paving the way for setting a Scope 3 target by 2025.
BeiGene’s commitment to environmental sustainability is evidenced by its announcement of a quantitative climate goal in 2023. The company aims to reduce its Scope 1 and 2 emissions by 25% per unit of internally manufactured commercial product by 2026 from a 2021 baseline. To achieve this, BeiGene is implementing energy efficiency projects and investing in renewable energy sources, such as solar panels on its manufacturing facilities.
In a bid to expand access to cancer treatments globally, BeiGene launched the BeiGene Foundation in early 2023. This independent nonprofit organization is dedicated to eliminating barriers to equitable and accessible cancer care in underserved communities worldwide. The foundation’s collaboration with the Max Foundation aims to provide access to BRUKINSA for the treatment of adult patients with chronic lymphocytic leukemia in 29 low- and middle-income countries over the next three years.
Christine Riley Miller, Global Head of Responsible Business & Sustainability at BeiGene, expressed pride in the company’s progress and reiterated its commitment to maximizing positive impact while minimizing negative effects on business, society, and the environment.
For further details regarding BeiGene’s Responsible Business & Sustainability strategy, achievements, and goals, the report can be downloaded from the company’s website.
About BeiGene:
BeiGene is a global oncology company dedicated to developing innovative and accessible cancer treatments worldwide. With a diverse portfolio, the company is accelerating the development of its pipeline through internal capabilities and collaborations, with a focus on improving access to medicines for patients in need.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Actual results may differ materially due to various important factors, including clinical trial results, regulatory actions, intellectual property protection, and financial considerations. Readers are advised to review BeiGene’s filings with the U.S. Securities and Exchange Commission for a comprehensive understanding of potential risks and uncertainties. All information is accurate as of the date of this press release, and BeiGene undertakes no obligation to update unless required by law.
